Welcome to our Investor Centre

For more than 20 years QBiotics has been refining our approach to the discovery and development of plant derived small molecule pharmaceuticals to address challenging medical conditions for humans and companion animals.

We are currently focused on oncology and wound healing, with an earlier programme in antibiotics ready to be brought into development once our current lead programmes are commercialised. Our diversity of indications, combined with our simultaneous development for the human and veterinary markets, means we have multiple ‘shots on goal’, ultimately reducing our overall risk profile while increasing our potential for success.

The QBiotics’ difference

01

Simultaneous human/veterinary development model delivers earlier returns

We take advantage of simultaneous development of our human and veterinary products. This has the duel outcome of providing early data in real world disease models to inform and support the human programmes.  In addition, veterinary products are quicker to market, creating early repeatable revenue streams for reinvestment into the higher value human products. Early veterinary clinical data provides initial proof of concept of our drugs, increasing the success potential and speed of human drug development. In return, the scientific rigor of the human program supports a high quality veterinary regulatory submission.

02

First marketed veterinary drug, STELFONTA®

Tigilanol tiglate has gained approval by the European Medicines Agency (EMA), Switzerland's Swissmedic and the Veterinary Medicines Directorate (VMD) in the United Kingdom as a veterinary oncology pharmaceutical brand name STELFONTA. The drug is also under late stage review by the US Food and Drug Administration – Center for Veterinary medicines (FDA-CVM), and Australian Pesticides and Veterinary Medicines Authority (APVMA). Tigilanol tiglate canine

03

Robust human development programme

QBiotics’ human oncology programme investigates the potential for our lead candidate tigilanol tiglate to treat a broad range of solid tumours (i.e. to be tumour agnostic). Three monotherapy trials are either underway or in late stage development in Head and Neck Squamous Cell Carcinoma (Phase IbIIa), melanoma (Phase IIb) and soft tissue sarcoma (Phase IIa).  In addition, a clinical  trial combining tigilanol tiglate with the MSD immune checkpoint inhibitor drug Keytruda is in late stage planning.

Our wound healing pharmaceutical EBC-1013 has the potential to bring a paradigm shift to the way we treat chronic and acute wounds and burns. Formal toxicology and CMC programs are well underway, leading to a first-in-human trial for our initial indication, venous leg ulcers. Products and Pipeline.

Antibiotics is a new area of interest with considerable potential for QBiotics. Our approach is to disarm bacteria (via virulence disruption) rather than kill them outright, thus producing less evolutionary pressure for development of bacterial resistance. We believe our programme could provide solutions to the continued rise of multiple resistant organisms.

04

Leading with purpose

Our global team of industry leaders is united by a common thread: our scientific excellence, combined with an ethical and principled approach to the business of pharmaceutical development and commercialisation. Meet our team

Resources

As an unlisted public company, we have an active secondary share market. If you are an existing shareholder, you can find information in this section on how to trade shares, and if you would like to access your holdings contact LINK Market Services, +61 1300 554 474 or email registrars@linkmarketservices.com.au